Health
CytoDel Announces Pre-Clinical Data on Cyto-111 as Antidote to Botulinum Neurotoxin (BoNT) Published in Science Translational Medicine – GlobeNewswire
Studies Show Cyto-111 Enables Delivery of Antibodies to Previously Inaccessible Intraneuronal Targets without the need for a Viral Vector or Transfection …
Studies Show Cyto-111 Enables Delivery of Antibodies to Previously Inaccessible Intraneuronal Targets without the need for a Viral Vector or Transfection
Supports the Development of New Approaches to Treat Multiple Neurological Diseases
NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) — CytoDel, Inc. (CytoDel or the Company), a privately-held corporation, today announces the publication of preclinical data on the Companys lead product, Cyto-111, in the peer-reviewed journal, Science Translational Medicine….
-
General16 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News23 hours agoDeath of German shepherd Arnie prompts Brisbane community action to protect pets caught up in crime
-
Noosa News17 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
Noosa News24 hours agoFrank Moneger identified as man accused of hit-and-run death of 17-year-old girl in Margate, Queensland